In a retrospective study, researchers determined whether the COVID-19 pandemic and COVID-19 infection affects disease course in patients with MS.
In an ongoing, longitudinal, observation study, researchers evaluated the effect of the timing of DMTs on processing speed in patients with MS.
In a single-center, retrospective study, researchers evaluated the effects of treatment with nDMTs compared with iDMTs in a cohort of patients with POMS.
Researchers sought to investigate the effect of the COVID-19 pandemic on physical activity in patients with MS.
Researchers sought to determine the efficacy of a lavender capsule on reducing fatigue symptoms in patients with MS.
Researchers sought to evaluate all-cause mortality at 30 days in patients with MS who were hospitalized at a VA center for COVID-19 between March 2020 and October 2021.
In a retrospective review, researchers sought to investigate the neurologic outcomes in patients with MS and related disorders following COVID-19 infection.
Using an analysis of combined data, researchers evaluated the dose-response relationship of 10, 20, and 40 mg ponesimod and the long-term safety and efficacy of poneismod 20 mg in patients with relapsing-remitting MS.
The researchers sought to determine whether the use of fluoxetine, riluzole, and amiloride led to an improvement in neuropathic pain compared with placebo in patients with SPMS in a trial.
The approval was based upon a bioavailability study in healthy adults comparing baclofen oral tablets to Lyvispah.